Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs Royal Medical Center

Two GLP-1 desks, one scoreboard. We put Sesame Care and Royal Medical Center head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 403 · Grade C

Royal Medical Center

Visit Royal Medical Center Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 55 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make Royal Medical Center a bad call — it's best for readers who want credentialed md founder with itemized dose-strength pricing. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
48
Supply Reliability
92
57
Transparency
94
72
Access Breadth
84
40
Clinical Oversight
80
62
Track Record
92
47
Sesame CareBrief Score 87 · 55Royal Medical Center

Price, coverage & the tracker

Sesame CareRoyal Medical Center
Brief Score87/100 (B+)55/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)Not disclosed
TirzepatideBrand Zepbound (price varies)From $450/mo (2.5 mg dose, compounded)
CoverageNationwide marketplaceCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Royal Medical Center: New to the tracker on 1 August 2026. The published line reads From $450/mo (2.5 mg dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.